The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRentokil Initial Regulatory News (RTO)

Share Price Information for Rentokil Initial (RTO)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 407.70
Bid: 406.40
Ask: 406.60
Change: 6.70 (1.67%)
Spread: 0.20 (0.049%)
Open: 408.90
High: 409.60
Low: 404.30
Prev. Close: 401.00
RTO Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Q3 Trading Update

19 Oct 2016 07:00

RNS Number : 8825M
Rentokil Initial PLC
19 October 2016
 

RENTOKIL INITIAL PLC (RTO)

THIRD QUARTER TRADING UPDATE

19 October 2016

 

 

 (£m)

Q3 2016

Growth

AER

AER

CER

Revenue

578.3

32.1%

15.7%

Revenue - ongoing operations1

576.7

33.1%

16.6%

 

 

Performance Overview (CER)

Revenue from ongoing operations increased by 16.6% in Q3, of which 3.1% was organic (H1 2016: 2.5%) and 13.5% was from acquisitions. Year to date we have delivered organic growth of 2.7%. Pest Control delivered an excellent performance in the quarter, growing organically by 5.9%, and our Hygiene business demonstrated further improvement, growing organically by 3.2%. Growth in our Emerging (+20.4%) and Growth (+26.3%) markets was once again particularly strong. Our operations within the Manage for Value quadrant grew by 2.3% while the rate of revenue decline in our Protect and Enhance markets was largely unchanged from Q1 and Q2 at 1%.

The majority of our regions have performed well in the period reflecting good performances in Asia, Pacific, Latin America, the UK and in our largest market, North America. While conditions remain tough in parts of Europe, particularly in France, overall the region delivered modest revenue growth in Q3.

Also in the quarter Rentokil was proud to provide in partnership with the Rio de Janeiro health authorities, Pest Control, including innovative mosquito elimination, in advance of and during the very successful Rio 2016 Olympic and Paralympic Games.

M&AThe Company acquired 13 businesses in the quarter including ten in Pest Control and two in Hygiene, as well as the acquisition of Residex, a Pest Control and Turf Products Distribution business, as announced on 7 July. All of the acquisitions were in Emerging or Growth markets. Combined annual revenues of the businesses acquired totalled £88m in the 12 months immediately prior to acquisition. For the nine months to 30 September we have acquired 33 businesses with combined annual revenues of £109m. The integrations of Steritech and Residex are both progressing well.

Commenting on today's announcement Andy Ransom, Chief Executive, said:

"I am pleased with our performance in the third quarter. Pest Control grew organically by almost 6%, reflecting good performances in Asia, Pacific, Latin America, the UK and our key growth market of North America. I am also encouraged by ongoing traction in our Hygiene business which delivered organic growth of 3.2%. Our guidance for the full year is unchanged."

Enquiries:

 

Investors / Analysts:

Katharine Rycroft

Rentokil Initial plc

07811 270734

Media:

Malcolm Padley

Rentokil Initial plc

07788 978 199

John Sunnucks

Bell Pottinger

0203 772 2549

 

 

 

AER - actual exchange rates; CER - constant 2015 exchange rates

 

1ongoing revenue excludes the financial performance of disposed and closed businesses but includes results from acquisitions

 

This announcement contains statements that are, or may be, forward-looking regarding the group's financial position and results, business strategy, plans and objectives. Such statements involve risk and uncertainty because they relate to future events and circumstances and there are accordingly a number of factors which might cause actual results and performance to differ materially from those expressed or implied by such statements. Forward-looking statements speak only as of the date they are made and no representation or warranty, whether expressed or implied, is given in relation to them, including as to their completeness or accuracy or the basis on which they were prepared. Other than in accordance with the Company's legal or regulatory obligations (including under the Listing Rules and the Disclosure and Transparency Rules), the Company does not undertake any obligation to update or revise publicly any forward-looking statement, whether as a result of new information, future events or otherwise. Information contained in this announcement relating to the Company or its share price, or the yield on its shares, should not be relied upon as an indicator of future performance. Nothing in this announcement should be construed as a profit forecast.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
QRTFMMMGVRFGVZM
Date   Source Headline
29th Jul 20217:00 amRNSInterim Results
8th Jul 20217:00 amRNSNotice of termination of guarantee
11th Jun 20211:50 pmRNSNotice of Early Redemption
12th May 20216:03 pmRNSResult of AGM
22nd Apr 20217:00 amRNSQ1 Trading Update
7th Apr 20212:01 pmRNSDirector/PDMR Shareholding
1st Apr 20216:30 pmRNSDirector/PDMR Shareholding
1st Apr 202110:23 amRNSBlock listing Interim Review
1st Apr 202110:16 amRNSChange of Registered Office
31st Mar 20214:00 pmRNSDirector/PDMR Shareholding
31st Mar 20211:16 pmRNSTotal Voting Rights
31st Mar 202110:33 amRNSAnnual Financial Report
30th Mar 20216:23 pmRNSDirector Declaration
24th Mar 20215:55 pmRNSDirector/PDMR Shareholding
12th Mar 20219:00 amRNSAdditional Listing
4th Mar 20217:05 amRNSDirectorate Change
4th Mar 20217:00 amRNSFinal Results
17th Feb 20215:45 pmRNSDirector Declaration
8th Jan 20217:00 amRNSQ4 2020 Acquisitions and Trading Update
27th Nov 20202:25 pmBUSEarly Repurchase(s)
27th Nov 20202:22 pmBUSEarly Repurchase(s)
24th Nov 20205:25 pmRNSDirector/PDMR Shareholding
20th Nov 20207:00 amRNSResult of Tender Offer for Notes due 2021
12th Nov 20209:02 amRNSTender Offer for Notes due 2021
22nd Oct 20207:00 amRNSQ3 Trading Update
8th Oct 20207:00 amRNSSuccessful EUR600m 8-year bond transaction priced
1st Oct 20209:00 amRNSBlock listing Interim Review
28th Aug 20203:40 pmRNSDirector/PDMR Shareholding
7th Aug 20205:24 pmRNSDirector/PDMR Shareholding
30th Jul 20207:00 amRNSInterim Results
6th Jul 20207:00 amRNSDirectorate Change
21st May 202011:00 amRNSDirector/PDMR Shareholding
13th May 20205:15 pmRNSResult of AGM
7th May 20204:45 pmRNSDirector/PDMR Shareholding
27th Apr 20203:50 pmRNSDisclosure of Rights Attached to Equity Shares
17th Apr 202011:59 amRNSDirector/PDMR Shareholding
16th Apr 20207:00 amRNSQ1 Trading Update
14th Apr 20205:26 pmRNSHolding(s) in Company
9th Apr 20204:35 pmRNSDirector/PDMR Shareholding
2nd Apr 20201:36 pmRNSDirector/PDMR Shareholding
1st Apr 20205:33 pmRNSConfirmation of Non-Executive Director Appointment
1st Apr 20209:24 amRNSBlock listing Interim Review
31st Mar 20202:18 pmRNSTotal Voting Rights
30th Mar 202012:37 pmRNSRedemption of 4.5% debenture stock
30th Mar 202012:24 pmRNSRedemption of 5% debenture stock
27th Mar 202011:00 amRNSHolding(s) in Company
26th Mar 20204:41 pmRNSSecond Price Monitoring Extn
26th Mar 20204:36 pmRNSPrice Monitoring Extension
26th Mar 202011:29 amRNSAnnual Financial Report
25th Mar 20207:00 amRNSTrading Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.